Acrongenomics' Partner Molecular Vision Reaches Target of Sub-Micromolar Detection of Fluorescent Dye.GENEVA -- Acrongenomics Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AGNM) is pleased to announce that its partner Molecular Vision has reached its target of sub-molecular detection of fluorescent dye Noun 1. fluorescent dye - a yellow dye that is visible even when highly diluted; used as an absorption indicator when silver nitrate solution is added to sodium chloride in order to precipitate silver chloride (turns pink when no chloride ions are left in solution and . Using the small-scale demonstrator dem·on·stra·tor n. 1. One that demonstrates, such as a participant in a public display of opinion. 2. An article or product used in a demonstration. demonstrator Noun 1. devices first shown on March 8th 2007, Molecular Vision has continued to develop the detection of fluorescent dyes in a head-on geometry using its proprietary detection system based on organic light emitting diodes See LED. (OLEDs), microfluidic chips and organic photodetectors. Dye concentrations of 0.1 micromolar have now been reliably measured. With further improvements in the detection system, it is expected to achieve a detection limit of 0.01 micromolar in the near future. Chris Wright Chris Wright may refer to:
About Molecular Vision Ltd. Molecular Vision is a spin-out company of Imperial Innovations Ltd. The company was founded by three Imperial College London History Imperial College was founded in 1907, with the merger of the City and Guilds College, the Royal School of Mines and the Royal College of Science (all of which had been founded between 1845 and 1878) with these entities continuing to exist as "constituent colleges". researchers -- Prof. Donal Bradley, Prof. Andrew de Mello and Dr. John de Mello -- in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical analytical, analytic pertaining to or emanating from analysis. analytical control control of confounding by analysis of the results of a trial or test. instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets. Molecular Vision recently signed a major development contract with Acrongenomics Inc. to jointly exploit and commercialize the technology. About Acrongenomics Inc. Acrongenomics Inc. is a publicly traded company publicly traded company A company whose shares of common stock are held by the public and are available for purchase by investors. The shares of publicly traded firms are bought and sold on the organized exchanges or in the over-the-counter market. that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications. Important Information About Forward-Looking Statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price Trading price The price at which a security is currently selling. and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions. For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances CIRCUMSTANCES, evidence. The particulars which accompany a fact. 2. The facts proved are either possible or impossible, ordinary and probable, or extraordinary and improbable, recent or ancient; they may have happened near us, or afar off; they are public or , new information, future events, or for any other reason occurring after the date of this news release. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion